My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Tenofovir Disoproxil Fumarate (Tenofovir DF)
    Tenofovir Disoproxil Fumarate (Tenofovir DF)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1812
    CAS #: 202138-50-9Purity ≥98%

    Description: Tenofovir Disoproxil Fumarate (Tenofovir DF), the Fumarate salt of tenofovir, belongs to a class of antiretroviral drugs, it inhibits the activity of HIV reverse transcriptase by competing with the natural substrate deoxyadenosine 5’-triphosphate and, after incorporation into DNA, by DNA chain termination. It is an antiretroviral medication used to prevent and treat HIV/AIDS and to treat chronic hepatitis B. Shortly upon administration, tenofovir disoproxil fumarate rapidly goes through esterase hydrolysis removing the two ester groups and yielding tenofovir, which is a nucleotide analogue with anti-viral activity against HIV-1/2.

    References: Antimicrob Agents Chemother. 2006 Oct;50(10):3297-304; Antimicrob Agents Chemother. 2002 Mar;46(3):716-23.

    Related CAS#:147127-20-6 (Tenofovir); 206184-49-8 (hydrate); 379270-37-8 (alafenamide); 206184-49-8 (hydrate); 1571075-19-8 (aspartate); 201341-05-1 Tenofovir dsoproxil); 1236287-04-9 (Tenofovir maleate); 1392275-56-7 (Tenofovir alafenamide hemifumarate); 379270-38-9 (Tenofovir alafenamide fumarate); 1464851-21-5 [(Z)-9-Propenyladenine; (Z)-Mutagenic Impurity of Tenofovir Disoproxil]; 1446486-33-4 [9-Propenyladenine; Mutagenic Impurity of Tenofovir Disoproxil; Tenofovir Impurity 2]

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)635.51
    FormulaC19H30N5O10P.C4H4O4
    CAS No.202138-50-9
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 128 mg/mL (201.4 mM)
    Water:<1 mg/mL
    Ethanol: 44 mg/mL (69.2 mM)
    Other infoChemical Name: 9-((R)-2-((Bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine, fumarate
    InChi Key: VCMJCVGFSROFHV-WZGZYPNHSA-N
    InChi Code: InChI=1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1
    SMILES Code: NC1=C2C(N(C[[email protected]](OCP(OCOC(OC(C)C)=O)(OCOC(OC(C)C)=O)=O)C)C=N2)=NC=N1.O=C(O)/C=C/C(O)=O
    SynonymsGS-1278 Disoproxil Fumarate; Tenofovir DF; TDF; GS-4331-05; GS4331-05; GS 4331-05; GS-433105; Tenofovir Disoproxil Fumarate; PMPA prodrug; Tenofovir DF; Viread; Bis(POC)-PMPA


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: Tenofovir is eliminated from systemic circulation renally through a combination of glomerular filtration and active tubular secretion. Tenofovir is not a substrate for human organic cation transporter type 1 (hOCT1) or hOCT2. Tenofovir accumulates to fivefold lower levels in MRP4-overexpressing cells, and its accumulation could be increased by an MRP inhibitor. Tenofovir produces no significant changes in mitochondrial DNA (mtDNA) levels in human hepatoblastoma (HepG2) cells, skeletal muscle cells (SkMCs), or renal proximal tubule epithelial cells. Tenofovir elevates lactate production by less than 20% in HepG2 cells or SkMCs. Tenofovir is efficiently phosphorylated to tenofovir diphosphate (TFV-DP) in both HepG2 cells and primary human hepatocytes. Tenofovir has a 50% effective concentration of 1.1 mM against HBV in cell-based assays, and potency is improved > 50-fold by the addition of bis-isoproxil progroups. Tenofovir has previously demonstrated full activity against lamivudine-resistant HBV in vitro and clinically. Tenofovir inhibits the proliferation of liver-derived HepG2 cells and normal skeletal muscle cells with CC(50) values of 398 mM and 870 mM, respectively. Tenofovir shows substantially weaker effects on proliferation and viability of renal proximal tubule epithelial cells than cidofovir, a related nucleotide analog with the potential to induce renal tubular dysfunction.


    Cell Assay: Cells are plated into 48-well tissue culture plates (39,000 cells/mL) and allowed to grow for 48 h followed by treatment with vehicle or Tenofovir. Following the treatment period, cell viability is assessed using the MTT assay. The MTT assay relies on the conversion of tetrazolium dye 3-(4,5-dimethlthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan by NAD(P)H-dependent oxidoreductases.

    In VivoTenofovir (30 mg/kg) completely prevents SIV infection in all macaques without toxicity. Tenofovir treatment reduces plasma viral RNA levels to undetectable, with parallel decreases in the infectivity of plasma and infectious cells in peripheral blood mononuclear cells and cerebrospinal fluid (CSF) and stabilization of CD4+ T-cell numbers. Tenofovir (30 mg/kg, s.c.) completely abrogates HIV infection via intravaginal exposure in pig-tailed macaques.
    Animal modelMacaques 
    Formulation & DosageDissolved in saline; 30 mg/kg; s.c. injection
    ReferencesAntivir Ther. 2004 Feb;9(1):57-65; Clin Microbiol Rev. 2003 Oct;16(4):569-96; Antimicrob Agents Chemother. 2006 Oct;50(10):3297-304; Antimicrob Agents Chemother. 2002 Mar;46(3):716-23.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    Tenofovir Disoproxil Fumarate

    Effects of tenofovir and other NRTIs on mtDNA content in skeletal muscle cells. Antimicrob Agents Chemother. 2002 Mar;46(3):716-23.
     

    Tenofovir Disoproxil Fumarate

    Effects of ddC, ddI, and tenofovir on the expression of COX II and COX IV in HepG2 cells. Antimicrob Agents Chemother. 2002 Mar;46(3):716-23.


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Email: sales[email protected]
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?